Browse the evidence

Discontinuation of second-generation OMMs leads to significant weight regain, highlighting the chronic nature of obesity and the need for long-term management or intensive lifestyle support upon discontinuation.

Stopping OMMs typically leads to significant weight regain. If you choose to discontinue, work with your healthcare provider to intensify lifestyle interventions, including dietary strategies and physical activity, to help maintain your weight loss.

Liraglutide (3.0 mg daily) is effective for weight loss but significantly less so than Semaglutide, with a mean weight loss of 6.4% compared to 15.8%.

Liraglutide (3.0 mg daily) is an FDA-approved option for weight loss, but it produces roughly half the weight loss of Semaglutide (6.4% vs 15.8%). It requires daily injections, which may be burdensome, and you must reach the 3.0 mg dose to see full effects. If you cannot tolerate Semaglutide, this is a viable alternative, but expect less dramatic results.

Once-weekly subcutaneous semaglutide (2.4 mg) significantly alters the circulating proteome in individuals with obesity, downregulating proteins associated with cardiovascular disease risk and inflammatory pathways beyond what is explained by weight loss and glycemic control alone.

If you have obesity and are considering semaglutide, know that it does more than just help you lose weight. It actively changes your blood proteins to lower your risk of heart disease and inflammation, even independent of the weight you lose. This makes it a valuable tool for cardiovascular protection in high-risk individuals, not just a weight-loss aid. The benefits are supported by large, rigorous clinical trials.

Genetically modeled GLP-1 and GIP receptor agonism reduces fatty food liking and increases vegetarian food liking.

Genetic evidence suggests that activating GLP-1 and GIP receptors shifts food preferences away from fatty foods and towards vegetarian options. This change in food preference may contribute to the observed reduction in binge drinking.

Tirzepatide treatment (10 mg or 15 mg once weekly for 72 weeks) significantly improves self-reported health-related quality of life (HRQoL) in adults with obesity or overweight and type 2 diabetes, specifically in physical functioning, bodily pain, general health, vitality, and social functioning.

If you have type 2 diabetes and are overweight or obese, treatment with tirzepatide (Mounjaro/Zepbound) can significantly improve your daily quality of life. This includes feeling less pain, having more energy, and being more socially active. The improvements are seen in both physical and mental well-being, and they are greater for those who lose more weight. Talk to your doctor about whether this once-weekly injection is right for you, especially if you are struggling with physical limitations due to your weight.

Glucagon regulates glucose and amino acid homeostasis and counters hypoglycemia.

Glucagon is a natural hormone that helps keep your blood sugar and amino acid levels stable. It acts as a counter-regulatory mechanism to prevent hypoglycemia, making it essential for metabolic balance.

GLP-1 receptor agonists (GLP-1RAs) such as liraglutide and semaglutide significantly reduce major adverse cardiovascular events (MACE) in patients with type 2 diabetes at high cardiovascular risk.

If you have Type 2 Diabetes and are at high risk for heart problems, ask your doctor about GLP-1 RAs like liraglutide or semaglutide. These drugs not only help control blood sugar but have been proven in major studies to significantly lower your risk of heart attack, stroke, and cardiovascular death. The benefits extend beyond glucose control to direct heart protection.

Obesity is a chronic disease driven by dysfunctional adipose tissue and dysregulated energy homeostasis, requiring medical treatment rather than solely lifestyle changes.

Obesity is a medical condition, not a moral failing. If you have obesity, you need medical treatment, not just willpower. Seek a doctor who understands this and offers evidence-based therapies.

Obesity acts as an independent risk factor and driver for cardiovascular diseases through mechanisms including insulin resistance, endothelial dysfunction, systemic inflammation, and neurohormonal activation, leading to hypertension, heart failure, coronary artery disease, and stroke.

High body weight is a major biological driver of heart disease, not just a cosmetic issue. Addressing it requires medical and public health strategies, not just willpower, because it triggers harmful biological changes like inflammation and high blood pressure.

GLP-1 receptor agonists (e.g., semaglutide) and dual agonists (e.g., tirzepatide) are effective pharmacotherapies for obesity, achieving 10-20% mean body weight reduction, but their use is limited by stigma, regulatory barriers, and lack of insurance coverage.

If you have obesity, ask your doctor about GLP-1 receptor agonists (like semaglutide) or dual agonists (like tirzepatide). These are proven to help with significant weight loss. If insurance doesn't cover them, advocate for policy changes or look for patient assistance programs.

GLP-1 receptor agonists (GLP-1RAs) induce weight loss primarily through central nervous system (CNS) mechanisms, specifically by acting on GLP-1 receptors in the dorsal vagal complex (NTS and area postrema) and hypothalamic nuclei, rather than through peripheral signaling alone.

GLP-1 medications like semaglutide work by signaling to your brain to reduce hunger and food intake, not just by slowing digestion. Understanding this brain-gut connection helps explain why these drugs are effective for weight loss and why side effects like nausea occur via specific brain pathways.

For patients with Class II obesity (BMI 35-39.9 kg/m2), tirzepatide is significantly superior to other medications and endoscopic procedures, but its weight loss efficacy is inferior to major surgeries like Roux-en-Y gastric bypass (RYGB) and One-Anastomosis Gastric Bypass (OAGB).

If you have Class II obesity (BMI 35-39.9), surgery (like gastric bypass) will likely help you lose more weight than medication. However, if you are not ready for or cannot undergo surgery, newer medications like tirzepatide are still significantly more effective than other non-surgical options, though they will not achieve the same level of weight loss as surgery.

GLP-1 receptor agonists (GLP-1RAs) such as semaglutide and tirzepatide reduce body weight primarily by suppressing energy intake through activation of GLP-1 receptors in the central nervous system (CNS) and peripheral vagal afferent pathways, rather than by increasing energy expenditure.

GLP-1 medications like semaglutide and tirzepatide are highly effective for weight loss, primarily by reducing appetite and food intake through brain and gut signaling. They are taken once weekly. While they achieve significant weight loss (15-20%+ in trials), real-world results vary, and about a third of users may not lose enough weight to be clinically effective. Common side effects like nausea are frequent but often manageable with dose titration. These drugs are not a magic bullet for everyone, especially those with type 2 diabetes or lower starting weights, and require medical supervision.

Semaglutide (1.0 mg/week) significantly reduces major kidney disease events, slows eGFR decline, and lowers MACE risk in patients with type 2 diabetes and chronic kidney disease.

If you have type 2 diabetes and kidney disease, semaglutide (1 mg weekly) is a proven treatment to protect your kidneys from failing and reduce your risk of heart events. It is taken as a weekly injection, starting at a low dose to minimize side effects, and works alongside your current blood pressure medications.

Tirzepatide (up to 15 mg/week) reduces the risk of worsening heart failure and cardiovascular death in patients with heart failure with preserved ejection fraction (HFpEF) and obesity.

If you have heart failure with preserved ejection fraction and obesity, tirzepatide (up to 15 mg weekly) can help reduce your risk of heart failure worsening and cardiovascular death. It is taken as a weekly injection, escalated to the maximum tolerated dose.

GLP-1RAs confer cardiovascular protection by reducing the risk of major adverse cardiovascular events (MACE), including death from cardiovascular causes, nonfatal myocardial infarction, and nonfatal stroke, particularly in patients with established cardiovascular disease and obesity.

If you have obesity and existing heart disease, GLP-1 receptor agonists like semaglutide can significantly reduce your risk of heart attack, stroke, and cardiovascular death. This benefit is independent of whether you have diabetes, making these medications a crucial part of cardiovascular risk management for obese patients.

Obesity medications (OMs) such as semaglutide and tirzepatide provide benefits for adiposity-related conditions independent of weight reduction.

If you are considering obesity medications, ask your doctor about their potential benefits beyond weight loss, such as reducing cardiovascular risk or improving sleep apnea. These benefits may be significant even if weight loss is modest.

Semaglutide (GLP-1 receptor agonist) significantly reduces major adverse cardiovascular events (MACE) in high-risk patients with type 2 diabetes and established cardiovascular disease.

If you have type 2 diabetes and existing heart disease or high risk, ask your doctor about semaglutide. It is a once-weekly injection that has been proven to significantly reduce the risk of heart attacks, strokes, and cardiovascular death.

Semaglutide slows the progression of chronic kidney disease (CKD) and reduces major kidney disease events in patients with type 2 diabetes.

If you have type 2 diabetes and chronic kidney disease, ask your doctor about semaglutide. It is a once-weekly injection that has been proven to significantly slow the progression of kidney disease and reduce the risk of major kidney events.

Increased BMI causally increases the risk of coronary artery disease and heart failure, independent of traditional risk factors like blood pressure and diabetes, though these factors mediate a significant portion of the risk.

High body weight directly harms the heart, even if your blood pressure and cholesterol are managed with medication. This is because excess fat tissue itself causes inflammation and stress on the cardiovascular system. Losing weight reduces this independent risk, protecting your heart beyond just improving numbers like blood pressure.

Central adiposity (measured by waist-to-hip ratio) is a stronger predictor of cardiometabolic risk than overall body mass index (BMI), primarily due to visceral fat and limited subcutaneous storage capacity leading to ectopic lipid deposition.

Don't just look at the scale. Where you store fat is critical. Excess fat around your waist (visceral fat) is biologically active and releases harmful substances that lead to diabetes and heart disease, even if your overall weight is normal. Measuring your waist circumference is a better indicator of risk than BMI alone.

GLP-1 receptor agonists (GLP-1RAs) provide significant cardiorenal protection in patients with type 2 diabetes and obesity, reducing major adverse cardiovascular events (MACE) and slowing kidney disease progression independent of, or in addition to, glycemic control and weight loss.

If you have type 2 diabetes or obesity with heart/kidney risks, GLP-1 medications (like semaglutide or liraglutide) are highly effective. They don't just lower blood sugar; they significantly reduce the risk of heart attacks, strokes, and kidney failure. While they can cause temporary stomach upset, the long-term benefits for your heart and kidneys are substantial and proven by large clinical trials. Discuss these options with your doctor, especially if you have existing heart or kidney conditions.

Semaglutide significantly improves MASH resolution and reduces liver steatosis and enzymes, but does not significantly improve fibrosis regression, with efficacy increasing at doses ≥2.0 mg/week and durations ≥12 months.

If you have MASH, semaglutide is a strong option to resolve active liver inflammation and reduce liver fat, especially if you can tolerate doses of 2.0 mg/week or higher for at least a year. However, do not expect it to reverse existing liver scarring (fibrosis). The primary benefit is halting active injury and reducing metabolic risk factors like weight and blood sugar, which indirectly protects the liver.

Semaglutide and tirzepatide reduce cardiovascular risk and improve cardiac function through pleiotropic mechanisms including endothelial protection, anti-inflammation, and inhibition of cardiomyocyte apoptosis, independent of glycemic control.

If you have obesity and existing heart disease, semaglutide (2.4 mg weekly) significantly lowers your risk of heart attack, stroke, and cardiovascular death, even if you do not have diabetes. This benefit comes from direct protection of your blood vessels and heart muscle, not just weight loss.